FDA panel to review BMS's belatacept
This article was originally published in Scrip
Executive Summary
The US FDA's cardiovascular and renal drugs advisory committee plans to meet on March 1st to review Bristol-Myers Squibb's injectable immunosuppressant belatacept for the prevention of organ rejection following kidney transplantation.